Evoke Pharma, Inc.

Good afternoon and welcome to the Evoke Pharma fourth quarter and full year 2023 earnings conference call. Currently all callers have been placed in a listen-only mode and following management's prepared remarks the call will be opened up for questions. If you would like to ask a question at that time please press star 1 on your telephone keypad. If you need to remove yourself from the queue press star 2. At any time if you should need operator assistance Press star zero. Please be advised that today's call is being recorded. I'll now turn the call over to Daniel Canto of Boeing. Please go ahead, sir.

Good afternoon, and thank you for participating in the Evoque Farmers Conference call and webcast today. With me today are Dave Garnier, Evoque's Chief Executive Officer, Chris Questenberry, Jamodi's Chief Commercial Officer from Eversana, and Matt D'Onofrio, Evoque's President and Chief Operating Officer. By now, you should have a copy of the press release we issued earlier. If not, it is available on the investor relations page of our website at evokepharma.com. We encourage everyone to read today's press release as well as Evoque's annual report on Form 10-K, which is now filed with the SEC. The company's Form 10-K and earnings release are also available on Evoque's website. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigations Reform Act. We caution listeners that during this call, management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risk and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Evoque's press releases and SEC filings, including its annual report on Form 10-K and subsequent filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Evoque undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call and webcast. With that, I would now like to turn the call over to David Donier. Dave?

Thank you, Daniel, and thanks, everyone, for joining the call this afternoon. As was described in today's press release, 2023 marked a milestone in EVOC's journey, not just commercially, but also in fulfilling our core mission, which is ensuring GMOTI is within reach for every patient who needs it. Let me tell you why this core mission is so important. It's because it's about the patient and their experiences that can and will fuel the progress, help us fuel the progress as an organization. A testament to our efforts comes from the countless positive stories we've been told from healthcare providers, patients, and our own sales representatives who hear and tell us some amazing patient success stories on a daily basis. While gastroparesis impacts predominantly women, today I'd like to share just a brief, very inspiring story that was just shared to us this week about a 30-year-old male who battles both type 1 diabetes and severe gastroparesis. This man, who was in and out of the hospital just about every month because of his gastroparesis, shared with his health care provider that since starting on Gemoti, he hasn't had a single hospital visit, not one. And to his admission, it's been life-changing for him. It's stories like these that will push payers, providers, and advocates to fight for patients who suffer from this insidious disease so they can receive the best care possible. Now, this is just one of many affirmations we have heard that continues to energize our commitment. Now, while we're humbled to see these stories of success, we also want to encourage providers to do more to diagnose and treat these patients with gastroparesis. But unfortunately, The norm for patients is to wait years before they're diagnosed and then often told there's not much they can do, can be done for them. When treatment is prescribed, all too often payers are pushing the cost to the patient or outright denying coverage. Payers can do better and patients deserve better treatment. The compelling evidence for Jimoni goes beyond anecdotes. The scientific groundwork the publication of our Phase III clinical data, and the peer-reviewed and plenary presentations of our real-world health resource utilization studies at leading gastroenterology congresses, demonstrating a reduction in emergency room and hospital visits, and a significant total healthcare cost savings compared to oral medical optimize, underscores the value of GMODI versus the current gold standard. Our story is really simple. and straightforward, and it's shaping up to be very compelling as well. Gemoti achieves rapid and direct absorption in the bloodstream. Gemoti provides documented symptomatic relief as early as one week, and now Gemoti shows improved outcomes versus oral metoclopramide. The drug delivery through the nose avoids the problem of the disease, which is an inability to predictably deliver pills into the small intestine to be absorbed. Importantly, many patients previously on oral medical reminds in the HRU study or the health resource utilization study who were switched to Gemoti, likely because they were not doing well, experienced the same reduction in ER visits and hospitalizations while taking Gemoti, confirming its place as a transformative medicine in gastroparesis treatment. Now, let me switch gears a bit and turn to some highlights for 2023. I'm happy to report that we doubled our net revenue for Gemoti over the last year. The number of new prescriptions grew by a notable 86%, and the total prescriptions dispensed increased by 101% year-over-year, clearly demonstrating the growing demand for Gemoti. We also augmented our prescriber base by 72% while amplifying the depth of their prescribing by 36%. Our commercial team's relentless focus propelled our targeting and outreach to healthcare providers, driving our financial achievements above our expectations. At important gastroenterology gatherings such as Digestive Disease Week and the American College of Gastroenterology conferences, Our data was selected by the respective governing boards for plenary presentations at both meetings. This is a testament to the strength and importance of the health resource utilization study we performed. This data highlighted Jamodi's role in significantly reducing ER visits and hospitalizations, outperforming oral medical provide and delivering care at a reduced price. This evidence not only resonated with GI professionals, but also underscores our commitment to patient care and economic efficiency for payers. Further in our strategic initiatives, we transitioned our pharmacy services to Aspen. The strategic alignment with Aspen's robust platform positions us to better meet our distribution needs, enhance patient access, and streamline our services. And Chris will elaborate a little bit more on this in a moment. Looking back on a year of dynamic growth, our strategic investments have paid dividends. We've not only strengthened the belief in GMODI, but doubled the patient count on therapy. As we lean into 2024, we're aiming high with a projected net revenue of approximately $14 million, nearly tripling our 2023 performance. And with that, let me turn it over to Chris to talk about our current commercialization activities and plans moving forward for this year.